Solubility and dissolution rate enhancement of ibuprofen by co-milling with polymeric excipients

被引:46
作者
Hussain, Amjad [1 ,2 ]
Smith, Geoff [2 ]
Khan, Karrar A. [2 ]
Bukhari, Nadeem Irfan [1 ]
Pedge, Nicholas, I [3 ]
Ermolina, Irina [2 ]
机构
[1] Univ Punjab, Univ Coll Pharm, Lahore, Pakistan
[2] De Montfort Univ, Leicester Sch Pharm, Leicester, Leics, England
[3] AstraZeneca, Pharmaceut Technol & Dev, Macclesfield, Cheshire, England
关键词
Poor soluble drugs; Ball milling; Solubility enhancement; Dissolution rate; Particle size; Amorphous content; WATER-SOLUBLE DRUG; SOLID-STATE; HYDROPHILIC CARRIERS; BIOAVAILABILITY; DISPERSIONS; HYDROCHLORIDE; COMMINUTION; IMPROVEMENT; PARTICLES; BEHAVIOR;
D O I
10.1016/j.ejps.2018.08.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to enhance the kinetic solubility and dissolution rate of ibuprofen by co-milling with different excipients and to establish the underlying mechanism(s) for such enhancement. In the first-part, two excipients (HPMC and soluplus) were selected from seven, and the optimal ball-milling parameters of speed and time (18 Hz, 15 min) were determined based on solubility-enhancement and flow-ability criteria. In the second-part, co-milling of different weight-ratios of ibuprofen-to-excipient was carried out and solubility and dissolution rates were determined. Mechanisms of biopharmaceutical enhancement were studied by SEM, laser diffraction, DSC, and FTIR analysis of the co-mixtures. Ibuprofen solubility (0.09 mg/mL for un-milled) was increased by factors of 4-5 and 10-20 for HPMC and soluplus, respectively. The weakening of crystals, stabilization of the amorphous phase and an increase in solid-state hydrogen bonding are the likely mechanisms for this enhancement. Reductions in Q70% dissolution time were also observed, by a factor of 4 and 7 for ibuprofen:HMPC and ibuprofen:soluplus co-milled mixtures, respectively. Although, there were similar reductions in particle size, dispersibility and degree of amorphization in both mixtures, the higher dissolution rate for soluplus, over that for HPMC, must be due to the additional solubilization contribution to the kinetic solubility provided by soluplus.
引用
收藏
页码:395 / 403
页数:9
相关论文
共 42 条
[1]   Development of stability-enhanced ternary solid dispersions via combinations of HPMCP and Soluplus® processed by hot melt extrusion [J].
Albadarin, Ahmad B. ;
Potter, Catherine B. ;
Davis, Mark T. ;
Iqbal, Javed ;
Korde, Sachin ;
Pagire, Sudhir ;
Paradkar, Anant ;
Walker, Gavin .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 532 (01) :603-611
[2]   Cogrinding as an approach to enhance dissolution rate of a poorly water-soluble drug (gliclazide) [J].
Barzegar-Jalali, Mohammad ;
Valizadeh, Hadi ;
Shadbad, Mohammad-Reza Siahi ;
Adibkia, Khosro ;
Mohammadi, Ghobad ;
Farahani, Amin ;
Arash, Zeynab ;
Nokhodchi, Ali .
POWDER TECHNOLOGY, 2010, 197 (03) :150-158
[3]  
Brittain H.G., 2014, Am. Pharm. Rev
[4]  
Brunton L.L., 2006, Goodman Gilman's The Pharmacological Basis of Therapeutics, V11
[5]   Amorphous Solid Dispersions of Sulfonamide/Soluplus® and Sulfonamide/PVP Prepared by Ball Milling [J].
Caron, Vincent ;
Hu, Yun ;
Tajber, Lidia ;
Erxleben, Andrea ;
Corrigan, Owen I. ;
McArdle, Patrick ;
Healy, Anne Marie .
AAPS PHARMSCITECH, 2013, 14 (01) :464-474
[6]  
Chowdary K, 2012, INT J RES PHARM CHEM, V2, P1043
[7]   Evidence for a New Crystalline Phase of Racemic Ibuprofen [J].
Dudognon, Emeline ;
Danede, Florence ;
Descamps, Marc ;
Correia, Natalia T. .
PHARMACEUTICAL RESEARCH, 2008, 25 (12) :2853-2858
[8]   Quantitative analysis of chlorpheniramine maleate and phenylephrine hydrochloride in nasal drops by differential-derivative spectrophotometric, zero-crossing first derivative UV spectrophotometric and absorbance ratio methods [J].
Erk, N .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 23 (06) :1023-1031
[9]  
Fisher E. S., 2007, ENCY PHARM TECHNOLOG
[10]   Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers [J].
Friedrich, H ;
Nada, A ;
Bodmeier, R .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (08) :719-728